Oncolytics Biotech Inc. ONCY

Annual Quarterly

No quarterly revenue total was found in ONCOLYTICS BIOTECH INC.'s SEC filings.

Oncolytics Biotech Inc. (ONCY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.1 million. As of Jun 30, 2026 it held $4.1 million in cash and investments and $448,000 in total debt.

Revenue
—
Net income
$-9.44M
-2.2% vs prior quarter
Operating cash flow
$-8.14M
-11.6% vs prior quarter
Free cash flow
$-8.14M
-11.5% vs prior quarter
EPS
$-0.08
+0.0% vs prior quarter
Dividend per share
None
Shares outstanding
127.51M
+6.8% vs prior quarter
Net cash
$3.67M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ONCY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1129928

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Operating income
-$9.4M
-$9.3M
Net income
-$9.4M
-$9.2M
Diluted EPS
-$0.08
-$0.08
Operating cash flow
-$8.1M
-$7.3M
Free cash flow
-$8.1M
-$7.3M
Total assets
$7.7M
$8.2M
Total liabilities
$13.8M
$13.3M
Stockholders' equity
-$6.2M
-$5.1M
Cash and investments
$4.1M
$5.5M
Total debt
$448,000
$508,000

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Nov 4, 2026 Nov 4, 2026
8-K Current report
Other events
 Oct 27, 2026 Oct 27, 2026
8-K Current report
Other events
 Oct 20, 2026 Oct 20, 2026
8-K Current report
Other events
 Oct 14, 2026 Oct 14, 2026
8-K Current report
Other events
 Oct 13, 2026 Oct 12, 2026
8-K Current report
Other events
 Sep 29, 2026 Sep 29, 2026

All 1000 Oncolytics Biotech Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.